Enlicitide (decanoate)
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2861205-06-1
- Formel: C92H129FN14O17
- Molecular Weight:1722.09
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Enlicitide decanoate specifically binds to the LDL receptor-binding domain of PCSK9, blocks the interaction between PCSK9 and LDL receptor, prevents PCSK9 from degrading LDL receptors on the surface of hepatocytes, thereby increasing the number of available LDL receptors on hepatocyte surface, enhancing the hepatic clearance efficiency of low-density lipoprotein cholesterol (LDL-C) in the blood, and achieving potent lipid-lowering effects[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 2861205-06-1
-
Molecular Weight 1722.09
-
Formel C92H129FN14O17
-
Synonyms
MK-0616 (decanoate)
-
Sequence
Ala-{Dpr}-Phe-Trp-Pro-Thr-Tyr-Pro(Covalent bridge:Phe3-Pro5,Ala1-Trp4,Trp4-Pro8,Ala1-Pro8,D-Dpr2)
-
Sequence Shortening
A-{Dpr}-FWPTYP(Covalent bridge:Phe3-Pro5,Ala1-Trp4,Trp4-Pro8,Ala1-Pro8,D-Dpr2)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)